The IL-23/IL-17 axis in psoriatic arthritis

Autoimmun Rev. 2014 Apr-May;13(4-5):496-502. doi: 10.1016/j.autrev.2014.01.050. Epub 2014 Jan 11.


Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease, affecting both the skin and joints. Disease progression is associated with aberrant cytokine expression, and TNF blockade is the most successful therapy to date. However, not all patients are responsive to anti-TNF treatment, highlighting the need to better understand the cellular and molecular mechanisms that govern the disease. PsA associations with single nucleotide polymorphisms in IL23R as well as TRAF3IP2 (Act1), a molecule downstream of the IL-17 receptor (IL-17R), have linked the IL-23/IL-17 axis to disease pathology. Although both cytokines are implicated in PsA, a full picture of their cellular targets and pathogenic mechanisms has not yet emerged. In this review, we focus on the IL-23/IL-17 axis-elicited responses mediated by osteoclasts, keratinocytes and neutrophils. Expanding our understanding of the cellular and molecular mechanisms that dictate pathogenicity in PsA will contribute to developing novel treatment strategies to combat disease.

Keywords: IL-17; IL-23; NF-κB; Psoriatic arthritis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Arthritis, Psoriatic / immunology*
  • Arthritis, Psoriatic / metabolism
  • Arthritis, Psoriatic / pathology
  • Humans
  • Interleukin-17 / immunology*
  • Interleukin-23 / immunology*
  • Neutrophils / immunology
  • Osteoclasts / immunology
  • RANK Ligand / immunology


  • Interleukin-17
  • Interleukin-23
  • RANK Ligand